Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 18 Results

Title
Intervention Indication Therapeutic Area Year Actions
131I-omburtamab for neuroblastoma with central nervous system or leptomeningeal metastasis in paediatric patients Omburtamab I-131 (131I-mu8H9) Neuroblastoma Neurological Cancer 2019 View  |  Download
Asinercept (Apocept) for glioblastoma multiforme for first or second line Asunercept (Apocept; APG101) Glioma Neurological Cancer 2017 View  |  Download
Cabozantinib for previously treated locally advanced, unresectable or metastatic neuroendocrine tumours Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Neuroendocrine tumour Neurological Cancer 2024 View  |  Download
Dabrafenib with trametinib for treating paediatric BRAF V600 mutated high-grade or low-grade glioma Dabrafenib (Tafinlar; GSK2118436; dabrafenib mesilate) , Trametinib (Mekinist; TMT212; GSK-1120212B; GSK1120212; JTP-74057; trametinib dimethyl sulfoxide) Glioma Neurological Cancer 2022 View  |  Download
Depatuxizumab mafodotin for newly diagnosed EGFR‐amplified glioblastoma – first line Depatuxizumab mafodotin (ABT-414) , Temozolomide (Temodar; Temodal; SCH 52365) Glioma Neurological Cancer 2018 View  |  Download
Eflornithine with lomustine for treating recurrent anaplastic astrocytoma Eflornithine (CPP-1X; Difluoromethylornithine; DFMO; Vaniqa; eflornithine hydrochloride monohydrate) , lomustine Anaplastic astrocytoma Neurological Cancer 2023 View  |  Download
ERC1671 (Gliovac) for recurrent grade IV glioma Bevacizumab (Avastin; R 435; RG 405; RG 435) , ERC1671 (Gliovac) Glioma Neurological Cancer 2019 View  |  Download
LAM-561 in addition to radiation therapy and temozolomide for glioblastoma –adjuvant 2-hydroxyoleic acid (2-OHOA; LP561A1; LAM561) , Radiotherapy , Temozolomide (Temodar; Temodal; SCH 52365) Glioma Neurological Cancer 2021 View  |  Download
Lutetium oxodotreotide with octreotide for treating previously untreated advanced gastroenteropancreatic neuroendocrine tumour Lutetium oxodotreotide , Octreotide Gastroenteropancreatic neuroendocrine tumour Neurological Cancer 2023 View  |  Download
MTX-110 for newly-diagnosed diffuse intrinsic pontine glioma Panobinostat (MTX-110; Farydak; LBH589; LBH-589; panobinostat lactate anhydrous) Glioma Neurological Cancer 2019 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications